Therapeutic efficacy of esomeprazole in cotton smoke-induced lung injury model

Christina Nelson, Jameisha Lee, Kang Ko, Andrew G. Sikora, Mark D. Bonnen, Perenlei Enkhbaatar, Yohannes T. Ghebre

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Proton pump inhibitors (PPIs) are well-known antacid drugs developed to treat gastric disorders. Emerging studies demonstrate that PPIs possess biological activities that extend beyond inhibition of H+/K+ ATPase (proton pumps) expressed in parietal cells of the stomach. Some of the extra-gastric activities of PPIs include modulation of epithelial, endothelial, and immune cell functions. Recently, we reported that PPIs suppress the expression of several proinflammatory and profibrotic molecules, as well as enhance antioxidant mechanisms in order to favorably regulate lung inflammation and fibrosis in an animal model of bleomycin-induced lung injury. In addition, several retrospective clinical studies report that the use of PPIs is associated with beneficial outcomes in chronic lung diseases including idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Based on these preclinical and clinical observations, we hypothesized that PPIs ameliorate smoke-induced lung injury. Accordingly, we evaluated the pharmacological efficacy of the PPI esomeprazole in a mouse model of cotton smoke-induced lung injury. The animals were exposed to cotton smoke for 3-weeks in the presence or absence of esomeprazole treatment. We found that therapeutic administration of esomeprazole significantly inhibited the progression of fibrosis throughout the lungs of the animals in this group compared to controls. In addition, esomeprazole also reduced circulating markers of inflammation and fibrosis. Overall, our work extends the emerging anti-inflammatory and antifibrotic potential of PPIs and their role in modulation of chronic lung diseases.

Original languageEnglish (US)
Article number16
JournalFrontiers in Pharmacology
Volume8
Issue numberJAN
DOIs
StatePublished - Jan 26 2017

Fingerprint

Esomeprazole
Proton Pump Inhibitors
Lung Injury
Smoke
Stomach
Fibrosis
Therapeutics
Lung Diseases
Chronic Disease
Proton Pumps
Antacids
Idiopathic Pulmonary Fibrosis
Proton-Translocating ATPases
Bleomycin
Chronic Obstructive Pulmonary Disease
Pneumonia
Anti-Inflammatory Agents
Endothelial Cells
Animal Models
Retrospective Studies

Keywords

  • Fibrosis
  • Inflammation
  • Lung injury
  • Proton pump inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Therapeutic efficacy of esomeprazole in cotton smoke-induced lung injury model. / Nelson, Christina; Lee, Jameisha; Ko, Kang; Sikora, Andrew G.; Bonnen, Mark D.; Enkhbaatar, Perenlei; Ghebre, Yohannes T.

In: Frontiers in Pharmacology, Vol. 8, No. JAN, 16, 26.01.2017.

Research output: Contribution to journalArticle

Nelson, Christina ; Lee, Jameisha ; Ko, Kang ; Sikora, Andrew G. ; Bonnen, Mark D. ; Enkhbaatar, Perenlei ; Ghebre, Yohannes T. / Therapeutic efficacy of esomeprazole in cotton smoke-induced lung injury model. In: Frontiers in Pharmacology. 2017 ; Vol. 8, No. JAN.
@article{7eaecd21a77f4ba1b85822737b759226,
title = "Therapeutic efficacy of esomeprazole in cotton smoke-induced lung injury model",
abstract = "Proton pump inhibitors (PPIs) are well-known antacid drugs developed to treat gastric disorders. Emerging studies demonstrate that PPIs possess biological activities that extend beyond inhibition of H+/K+ ATPase (proton pumps) expressed in parietal cells of the stomach. Some of the extra-gastric activities of PPIs include modulation of epithelial, endothelial, and immune cell functions. Recently, we reported that PPIs suppress the expression of several proinflammatory and profibrotic molecules, as well as enhance antioxidant mechanisms in order to favorably regulate lung inflammation and fibrosis in an animal model of bleomycin-induced lung injury. In addition, several retrospective clinical studies report that the use of PPIs is associated with beneficial outcomes in chronic lung diseases including idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Based on these preclinical and clinical observations, we hypothesized that PPIs ameliorate smoke-induced lung injury. Accordingly, we evaluated the pharmacological efficacy of the PPI esomeprazole in a mouse model of cotton smoke-induced lung injury. The animals were exposed to cotton smoke for 3-weeks in the presence or absence of esomeprazole treatment. We found that therapeutic administration of esomeprazole significantly inhibited the progression of fibrosis throughout the lungs of the animals in this group compared to controls. In addition, esomeprazole also reduced circulating markers of inflammation and fibrosis. Overall, our work extends the emerging anti-inflammatory and antifibrotic potential of PPIs and their role in modulation of chronic lung diseases.",
keywords = "Fibrosis, Inflammation, Lung injury, Proton pump inhibitors",
author = "Christina Nelson and Jameisha Lee and Kang Ko and Sikora, {Andrew G.} and Bonnen, {Mark D.} and Perenlei Enkhbaatar and Ghebre, {Yohannes T.}",
year = "2017",
month = "1",
day = "26",
doi = "10.3389/fphar.2017.00016",
language = "English (US)",
volume = "8",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "JAN",

}

TY - JOUR

T1 - Therapeutic efficacy of esomeprazole in cotton smoke-induced lung injury model

AU - Nelson, Christina

AU - Lee, Jameisha

AU - Ko, Kang

AU - Sikora, Andrew G.

AU - Bonnen, Mark D.

AU - Enkhbaatar, Perenlei

AU - Ghebre, Yohannes T.

PY - 2017/1/26

Y1 - 2017/1/26

N2 - Proton pump inhibitors (PPIs) are well-known antacid drugs developed to treat gastric disorders. Emerging studies demonstrate that PPIs possess biological activities that extend beyond inhibition of H+/K+ ATPase (proton pumps) expressed in parietal cells of the stomach. Some of the extra-gastric activities of PPIs include modulation of epithelial, endothelial, and immune cell functions. Recently, we reported that PPIs suppress the expression of several proinflammatory and profibrotic molecules, as well as enhance antioxidant mechanisms in order to favorably regulate lung inflammation and fibrosis in an animal model of bleomycin-induced lung injury. In addition, several retrospective clinical studies report that the use of PPIs is associated with beneficial outcomes in chronic lung diseases including idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Based on these preclinical and clinical observations, we hypothesized that PPIs ameliorate smoke-induced lung injury. Accordingly, we evaluated the pharmacological efficacy of the PPI esomeprazole in a mouse model of cotton smoke-induced lung injury. The animals were exposed to cotton smoke for 3-weeks in the presence or absence of esomeprazole treatment. We found that therapeutic administration of esomeprazole significantly inhibited the progression of fibrosis throughout the lungs of the animals in this group compared to controls. In addition, esomeprazole also reduced circulating markers of inflammation and fibrosis. Overall, our work extends the emerging anti-inflammatory and antifibrotic potential of PPIs and their role in modulation of chronic lung diseases.

AB - Proton pump inhibitors (PPIs) are well-known antacid drugs developed to treat gastric disorders. Emerging studies demonstrate that PPIs possess biological activities that extend beyond inhibition of H+/K+ ATPase (proton pumps) expressed in parietal cells of the stomach. Some of the extra-gastric activities of PPIs include modulation of epithelial, endothelial, and immune cell functions. Recently, we reported that PPIs suppress the expression of several proinflammatory and profibrotic molecules, as well as enhance antioxidant mechanisms in order to favorably regulate lung inflammation and fibrosis in an animal model of bleomycin-induced lung injury. In addition, several retrospective clinical studies report that the use of PPIs is associated with beneficial outcomes in chronic lung diseases including idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Based on these preclinical and clinical observations, we hypothesized that PPIs ameliorate smoke-induced lung injury. Accordingly, we evaluated the pharmacological efficacy of the PPI esomeprazole in a mouse model of cotton smoke-induced lung injury. The animals were exposed to cotton smoke for 3-weeks in the presence or absence of esomeprazole treatment. We found that therapeutic administration of esomeprazole significantly inhibited the progression of fibrosis throughout the lungs of the animals in this group compared to controls. In addition, esomeprazole also reduced circulating markers of inflammation and fibrosis. Overall, our work extends the emerging anti-inflammatory and antifibrotic potential of PPIs and their role in modulation of chronic lung diseases.

KW - Fibrosis

KW - Inflammation

KW - Lung injury

KW - Proton pump inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85012117674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012117674&partnerID=8YFLogxK

U2 - 10.3389/fphar.2017.00016

DO - 10.3389/fphar.2017.00016

M3 - Article

VL - 8

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - JAN

M1 - 16

ER -